Fluoroquinolone is a type of drug used to prevent and treat infections. Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture. This risk is further increased in those over age 60, in kidney, heart, and lung transplant recipients, and with use of concomitant steroid therapy.
The use of ciprofloxacin and other antibiotics of the class of fluoroquinolones may be associated with disruption of the normal functions of connective tissue, including tendon rupture, tendonitis and retinal detachment
The U.S. Food and Drug Administration today is requiring safety labeling changes for a class of antibiotics called fluoroquinolones to strengthen the warnings about the risks of mental health side effects and serious blood sugar disturbances, and make these warnings more consistent across the labeling for all fluoroquinolones taken by mouth or given by injection.
Rates of C. difficile infections have decreased 36% in hospitals across Canada, although the virulent NAP1 strain associated with severe illness and deaths is the most common strain, according to research published in CMAJ.
New research from a Swedish and Danish team of researchers led from Karolinska Institutet lend additional support to a link between treatment with fluoroquinolone antibiotics and an increased risk of acute aortic disease. The study is published in the esteemed journal The BMJ.
The rising frequency and severity of Clostridium difficile infections may be caused by the commonly used food additive, trehalose, according to Nature.
The increasing frequency and severity of healthcare-associated outbreaks caused by bacterium Clostridium difficile have been linked to the widely used food additive trehalose.
Antibiotic resistance happens when bacteria evolve mechanisms to withstand the drugs which are used to treat infections.
According to a new report from the World Health Organization (WHO) released yesterday, antibiotics development at present is not at par with the rising antimicrobial resistance worldwide and soon the demand may outgrow the supply. The WHO warns that this could mean that pathogens causing these infections could mean a great threat for humans in the coming years.
Novel molecular tests are gaining popularity as a rapid way to detect genetic mutations that render tuberculosis impervious to drugs. Yet, how well these new tests fare in gauging risk of actual drug failure and patient death has remained unclear.
An international team of scientists have discovered a new class of compounds that inhibit bacterial DNA gyrase.
The new study presented at the 2017 American Thoracic Society International Conference has found that about 22.1%, approximately one in four adults, failed to respond to antibiotics for community-acquired pneumonia (CAP) treatment.
Approximately one in four (22.1 percent) adults prescribed an antibiotic in an outpatient setting (such as a doctor's office) for community-acquired pneumonia does not respond to treatment, according to a new study presented at the 2017 American Thoracic Society International Conference.
Directly observed therapy (DOT) for multidrug-resistant tuberculosis (MDR TB) was associated with a 77 percent decrease in mortality in the United States, compared to self-administered therapy from 1993 to 2013, according to new research presented at the ATS 2017 International Conference.
Scientists have developed a new method to clear antibiotic resistant bacteria from the surface of the eye – introducing a new strain of bacteria that preys on other microorganisms.
Scientists at St. Boniface Hospital Albrechtsen Research Centre and the University of Manitoba have developed a drug that combats 2 of the top 10 "priority pathogens" recently defined by the World Health Organization as antiobiotic-resistant bacteria requiring new interventions.
In a study that could have significant impact on how disease outbreaks are managed, researchers at UC Davis and the California Department of Public Health have sequenced and analyzed genomes from Shigella sonnei (S. sonnei) bacteria associated with major shigellosis outbreaks in California in 2014 and 2015.
During the winter months, patients frequently present with respiratory symptoms like coughing, sneezing and fever that could be caused by one of several bacterial and viral infections including influenza, respiratory syncytial virus (RSV) or bacterial pneumonia.
Experts at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) are joining colleagues across the globe this week to promote prudent use of antibiotics.
The increase in illnesses and deaths linked to medication-resistant bacteria has been well-documented by researchers and received extensive public attention in recent years. Now, UCLA-led research shows how these bacteria are making it more difficult to treat a common but severe kidney infection.
The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections.